AustralieFrV1, PubMed, Corpus, bibRecord, 000816

Azacitidine in adult patients with acute myeloid leukemia.

Identifieur interne : 000816 ( PubMed/Corpus ); précédent : 000815; suivant : 000817

Azacitidine in adult patients with acute myeloid leukemia.

Auteurs : Andre C. Schuh ; Hartmut Döhner ; Lisa Pleyer ; John F. Seymour ; Pierre Fenaux ; Hervé Dombret

Source :

Critical reviews in oncology/hematology [ 1879-0461 ] ; 2017.

RBID : pubmed:28693797

Abstract

Azacitidine is recommended front-line treatment for older patients with acute myeloid leukemia (AML) who are not candidates for intensive treatment regimens, and was recently granted approval in the European Union for treatment of adult AML. Reviewed here is azacitidine experience in AML, including: mechanistic and pharmacokinetic data; safety and efficacy in controlled trials; treatment effects in AML subpopulations defined by disease characteristics; experience in unselected patients treated in the community setting; clinical outcomes relative to other approved AML therapies; and experience with azacitidine-based combination treatment regimens. Collectively, these data suggest that (a) azacitidine may prolong overall survival to a similar or greater extent than do other approved AML treatments, but with less toxicity, (b) azacitidine may be the preferred treatment option for older patients with unfavorable cytogenetics, and (c) experience and outcomes with azacitidine in the clinic are similar to those seen in clinical trials. Continued investigation of combination regimens on an azacitidine backbone is warranted.

DOI: 10.1016/j.critrevonc.2017.05.010
PubMed: 28693797

Links to Exploration step

pubmed:28693797

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Azacitidine in adult patients with acute myeloid leukemia.</title>
<author><name sortKey="Schuh, Andre C" sort="Schuh, Andre C" uniqKey="Schuh A" first="Andre C" last="Schuh">Andre C. Schuh</name>
<affiliation><nlm:affiliation>Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address: andre.schuh@uhn.ca.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dohner, Hartmut" sort="Dohner, Hartmut" uniqKey="Dohner H" first="Hartmut" last="Döhner">Hartmut Döhner</name>
<affiliation><nlm:affiliation>Universitätsklinikum Ulm, Ulm, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pleyer, Lisa" sort="Pleyer, Lisa" uniqKey="Pleyer L" first="Lisa" last="Pleyer">Lisa Pleyer</name>
<affiliation><nlm:affiliation>3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Austria; Salzburg Cancer Research Institute - Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Austria.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Seymour, John F" sort="Seymour, John F" uniqKey="Seymour J" first="John F" last="Seymour">John F. Seymour</name>
<affiliation><nlm:affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Parkville, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fenaux, Pierre" sort="Fenaux, Pierre" uniqKey="Fenaux P" first="Pierre" last="Fenaux">Pierre Fenaux</name>
<affiliation><nlm:affiliation>Hôpital Saint Louis, Institut Universitaire d'Hématologie, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dombret, Herve" sort="Dombret, Herve" uniqKey="Dombret H" first="Hervé" last="Dombret">Hervé Dombret</name>
<affiliation><nlm:affiliation>Hôpital Saint Louis, Institut Universitaire d'Hématologie, Paris, France.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28693797</idno>
<idno type="pmid">28693797</idno>
<idno type="doi">10.1016/j.critrevonc.2017.05.010</idno>
<idno type="wicri:Area/PubMed/Corpus">000816</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000816</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Azacitidine in adult patients with acute myeloid leukemia.</title>
<author><name sortKey="Schuh, Andre C" sort="Schuh, Andre C" uniqKey="Schuh A" first="Andre C" last="Schuh">Andre C. Schuh</name>
<affiliation><nlm:affiliation>Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address: andre.schuh@uhn.ca.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dohner, Hartmut" sort="Dohner, Hartmut" uniqKey="Dohner H" first="Hartmut" last="Döhner">Hartmut Döhner</name>
<affiliation><nlm:affiliation>Universitätsklinikum Ulm, Ulm, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pleyer, Lisa" sort="Pleyer, Lisa" uniqKey="Pleyer L" first="Lisa" last="Pleyer">Lisa Pleyer</name>
<affiliation><nlm:affiliation>3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Austria; Salzburg Cancer Research Institute - Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Austria.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Seymour, John F" sort="Seymour, John F" uniqKey="Seymour J" first="John F" last="Seymour">John F. Seymour</name>
<affiliation><nlm:affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Parkville, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fenaux, Pierre" sort="Fenaux, Pierre" uniqKey="Fenaux P" first="Pierre" last="Fenaux">Pierre Fenaux</name>
<affiliation><nlm:affiliation>Hôpital Saint Louis, Institut Universitaire d'Hématologie, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dombret, Herve" sort="Dombret, Herve" uniqKey="Dombret H" first="Hervé" last="Dombret">Hervé Dombret</name>
<affiliation><nlm:affiliation>Hôpital Saint Louis, Institut Universitaire d'Hématologie, Paris, France.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Critical reviews in oncology/hematology</title>
<idno type="eISSN">1879-0461</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Azacitidine is recommended front-line treatment for older patients with acute myeloid leukemia (AML) who are not candidates for intensive treatment regimens, and was recently granted approval in the European Union for treatment of adult AML. Reviewed here is azacitidine experience in AML, including: mechanistic and pharmacokinetic data; safety and efficacy in controlled trials; treatment effects in AML subpopulations defined by disease characteristics; experience in unselected patients treated in the community setting; clinical outcomes relative to other approved AML therapies; and experience with azacitidine-based combination treatment regimens. Collectively, these data suggest that (a) azacitidine may prolong overall survival to a similar or greater extent than do other approved AML treatments, but with less toxicity, (b) azacitidine may be the preferred treatment option for older patients with unfavorable cytogenetics, and (c) experience and outcomes with azacitidine in the clinic are similar to those seen in clinical trials. Continued investigation of combination regimens on an azacitidine backbone is warranted.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28693797</PMID>
<DateCreated><Year>2017</Year>
<Month>07</Month>
<Day>11</Day>
</DateCreated>
<DateRevised><Year>2017</Year>
<Month>07</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0461</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>116</Volume>
<PubDate><Year>2017</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Critical reviews in oncology/hematology</Title>
<ISOAbbreviation>Crit. Rev. Oncol. Hematol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Azacitidine in adult patients with acute myeloid leukemia.</ArticleTitle>
<Pagination><MedlinePgn>159-177</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1040-8428(17)30113-0</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.critrevonc.2017.05.010</ELocationID>
<Abstract><AbstractText>Azacitidine is recommended front-line treatment for older patients with acute myeloid leukemia (AML) who are not candidates for intensive treatment regimens, and was recently granted approval in the European Union for treatment of adult AML. Reviewed here is azacitidine experience in AML, including: mechanistic and pharmacokinetic data; safety and efficacy in controlled trials; treatment effects in AML subpopulations defined by disease characteristics; experience in unselected patients treated in the community setting; clinical outcomes relative to other approved AML therapies; and experience with azacitidine-based combination treatment regimens. Collectively, these data suggest that (a) azacitidine may prolong overall survival to a similar or greater extent than do other approved AML treatments, but with less toxicity, (b) azacitidine may be the preferred treatment option for older patients with unfavorable cytogenetics, and (c) experience and outcomes with azacitidine in the clinic are similar to those seen in clinical trials. Continued investigation of combination regimens on an azacitidine backbone is warranted.</AbstractText>
<CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuh</LastName>
<ForeName>Andre C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo><Affiliation>Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address: andre.schuh@uhn.ca.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Döhner</LastName>
<ForeName>Hartmut</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Universitätsklinikum Ulm, Ulm, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pleyer</LastName>
<ForeName>Lisa</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Austria; Salzburg Cancer Research Institute - Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Seymour</LastName>
<ForeName>John F</ForeName>
<Initials>JF</Initials>
<AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Parkville, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fenaux</LastName>
<ForeName>Pierre</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Hôpital Saint Louis, Institut Universitaire d'Hématologie, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dombret</LastName>
<ForeName>Hervé</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Hôpital Saint Louis, Institut Universitaire d'Hématologie, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>06</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Crit Rev Oncol Hematol</MedlineTA>
<NlmUniqueID>8916049</NlmUniqueID>
<ISSNLinking>1040-8428</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AML</Keyword>
<Keyword MajorTopicYN="N">Acute myeloid leukemia</Keyword>
<Keyword MajorTopicYN="N">Azacitidine</Keyword>
<Keyword MajorTopicYN="N">CC-486</Keyword>
<Keyword MajorTopicYN="N">Decitabine</Keyword>
<Keyword MajorTopicYN="N">Induction chemotherapy</Keyword>
<Keyword MajorTopicYN="N">Low-dose cytarabine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>02</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2017</Year>
<Month>05</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>05</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>7</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>7</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>7</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28693797</ArticleId>
<ArticleId IdType="pii">S1040-8428(17)30113-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.critrevonc.2017.05.010</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000816 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000816 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:28693797
   |texte=   Azacitidine in adult patients with acute myeloid leukemia.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:28693797" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Azacitidine in adult patients with acute myeloid leukemia.

Azacitidine in adult patients with acute myeloid leukemia.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki